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Abstract
Hypercalcemia can causes life threatening complications. We report an infant with severe
hypercalcemia due to congenital mesoblastic nephroma. Hypercalcemia was corrected before
nephrectomy by pamidronate. According to our knowledge this is a rare case with severe neoplasm
induced hypercalcemia among neonates who treated by bisphosphonates. The aim of this report is
to define new approach to neoplasm induced neonatal hypercalcemia.
Introduction
In infants, hypercalcemia is a rare but serious condition.
Some causes of hypercalcemia in neonatal period include
severe primary hyperparathyroidism, homozygous famil-
ial hypocalciuric hypercalcemia, idiopathic infantile
hypercalcemia, William's syndrome, iatrogenic adminis-
tration of calcium (generally intravenously), vitamin A or
D intoxication and subcutaneous fat necrosis or as a form
of paraneoplastic syndromes. They can be complicated by
potentially life-threatening hypercalcemia which should
be investigated and treated without delay [1,2].
Life-threatening hypercalcemia is rare in infants and
young children. Pharmacological treatment of severe
hypercalcemia is complicated by lack of experience with
some effective medications such as bisphosphonates in
newborns.
Congenital mesoblastic nephroma is the most common
renal tumor in neonatal and early infantile period. It can
be associated with paraneoplastic syndromes, such as
hypertension and hypercalcemia [1].
We report a 9 day old newborn infant with history of pol-
yhydramnios, a right-sided renal mass duo to mesoblastic
nephroma, hypercalcemia and hypertension which was
treated with a bisphosphonate, pamidronate, to stabilize
life-threatening hypercalcemia before nephrectomy.
Case description
A 9-day old male newborn infant was admitted in our
hospital with history of poor feeding, vomiting, decreased
tonicity, lethargy, and dehydration since two days before.
He was the second-born child of non consanguineous
parents. His mother had history of polyhydramnios. He
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was the product of caesarian section because of polyhy-
dramnios. Birth weight was 3700 g, Apgar scores were nor-
mal and he was discharged at the first day of age.
On admission findings were as follows: heart rate 143/
min, respiratory rate 52/min, blood pressure (BP) 140/
110 mmHg, weight 2.30 kg. He had lost 1400 g since birth
and had a mild degree of hypotonia and hyporeflexia.
Physical examination revealed a large right-sided abdom-
inal mass with regular margins (Fig 1). Ultrasound exam-
ination showed a large echogenic and heterogeneous
mass composed cystic areas that was 85 × 65 mm con-
firmed.
Initial biochemical studies revealed serum calcium of 17
mg/dl (reference range 8.2-10.5 mg/dl). He had persistent
hypercalcemia (serum calcium > 15 mg/dl) for more than
6 hours before medical therapy. Other laboratory tests
were in normal ranges and serum Phosphorus and mag-
nesium were 3.8 mg/dl and 2 mg/dl respectively.
At first visit we tried normal saline and furosemide but no
obvious response was seen. Then the patient received two
intravenous pamidronate (1.5 mg/kg) for 2 days. Pamidr-
onate infused in 25 milliliter of 5% dextrose saline solu-
tion over 4 hours. His serum calcium level decreased
significantly, and about 18 hours later, his total calcium
level normalized and his symptoms recovered except
abdominal mass. Because our patient was hypertensive,
we prescribed nifedipine also. Unfortunately we do not
have the levels of serum PTH and specific markers of bone
turnover because were not measured.
After stabilization of hypercalcemia, successful right
nephrectomy was performed.
Histological evaluation of revealed a well circumscribed,
11 × 10 × 8 cm, round shape, smooth yellow mass in the
upper pole of the right kidney (Fig 2). On the microscopic
examination the lesion displayed bundles of spindle
shaped stromal cells with occasional entrapped normal
renal tubular and glomerular cell, findings that consistent
with diagnosis of mesoblastic nephroma (Fig 3). After
operation serum calcium level doesn't increase again. The
normal blood pressure achieved about 16 hours after
operation.
Discussion
We described a neonate with severe paraneoplastic hyper-
calcemia. Hypercalcemia in this situations, have been
reported to be caused by the tumor secretion of PTH, PTH-
related peptide [2], prostaglandin E2 [3] and glucagon-
like peptides [4]. When the total calcium concentration is
14 mg/dL, emergency intervention is necessary because of
life-threatening adverse effects of hypercalcemia on heart,
brain, kidney, and gastrointestinal function. Hypercal-
cemia that is an uncommon complication of childhood
cancers, has been reported in association with childhood
renal tumors in 1.2% of cases, compared with 0.7%
among childhood solid tumors in general [5,6].
Despite the response to pharmacological therapy with
hydration and furosemide diuresis, in many times is inad-
equate and transient, pharmacological treatment of
hypercalcemia with medications such as bisphosphonates
is complicated by lack of experience in newborns. We use
pamidronate, to stabilize hypercalcemia, prior to
The figure shows the huge abdominal mass dominant in right  side Figure 1
The figure shows the huge abdominal mass dominant 
in right side.
Gross picture of removed mass Figure 2
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nephrectomy. The serum calcium was successfully
decreased without any complications.
Fox et al for the first time described the use of pamidro-
nate to control marked hypercalcemia in neonatal hyper-
parathyroidism that resulted from an inactivating
mutation of the calcium-sensing receptor. They treated
their neonate, with intravenous pamidronate (20 mg/
m2). Six doses of 20 to 30 mg/m2 were given over the next
6 weeks with the aim of performing parathyroidectomy
once it was technically feasible and she was clinically sta-
ble [7]. Although total dose of pamidronate in this case
was higher than our patients but each prescribed pamidr-
onate doses was lower. It may due to lower calcium level
in their patient.
In another study by Alos et al, Four newborns presented
with subcutaneous fat necrosis complicated by severe
hypercalcemia were reported. Despite traditional treat-
ment, calcium levels persistently remained high. By using
3-4 doses of pamidronate (0.25-0.50 mg/kg/dose) cal-
cium levels decreased within 48-96 h [8].
Bryowsky et al reported a 17-day-old premature infant
who received 0.7 mg/kg of pamidronate for treatment of
hypercalcemia due to parenteral nutrition. His serum cal-
cium concentration returned to normal without any
adverse reaction. They also propose clinical trials in pedi-
atric patients are necessary to determine how best to use
bisphosphonates in these patient populations [9].
Despite a few studies like these, there are a few controlled
studies that have been performed on the use of pamidro-
nate, to stabilize life-threatening hypercalcemia among
newborns; therefore, dosing guidelines are not available.
Some mentions doses for intravenous pamidronate
administration in newborn studies for treatment of hyper-
calcemia resulting from different causes have varied from
0.35 to 1.2 mg/kg per dose or 0.25-0.50 mg/kg/dose [8].
In our case higher dose of tolerable pamidronate was
administered and therefore rapid response to treatment
was achieved in such critical emergent setting.
Conclusion
Intravenous pamidronate appears to be a safe and effec-
tive treatment for severe hypercalcemia among neonates
and infants with life-threatening paraneoplastic hypercal-
cemia. This could stabilize the patients before surgery
especially those who do not respond adequately to tradi-
tional treatments or when urgent surgery is impassible.
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